, Tracking Stock Market Picks
Enter Symbol:

Strong Buy
down 38.92 %

BIOTIME INC (BTX) rated Strong Buy with price target $8 by WBB Securities

Posted on: Monday,  Dec 19, 2011  9:25 AM ET by WBB Securities

WBB Securities rated Strong Buy BIOTIME INC (AMEX: BTX) on 12/19/2011. Previously WBB Securities rated Speculative Buy BIOTIME INC (AMEX: BTX) on
08/11/2011., when the stock price was $4.47. Since then, BIOTIME INC has lost 38.93% as of 08/24/2015's recent price of $2.73.
If you would have followed the previous WBB Securities's recommendation on BTX, you would have lost 38.92% of your investment in 1474 days.

BioTime, Inc. is a biomedical organization engaged in the development of synthetic plasma expanders and blood volume substitute solutions for use in surgery, trauma care, organ transplant procedures, and other areas of medicine. The Company?s operating revenues have been generated primarily from licensing fees related to the sale of its plasma volume expander products, primarily Hextend. The company began to make its first stem cell research products available during the year ended December 31, 2008, but it had not yet generated significant revenues in that business segment.

Research from WBB Securities provides investment professionals with up-to-date, in-depth, accurate and insightful reporting of companies that specialize in biotechnology, medical devices and healthcare. Our goal is to provide independent, straight-forward and up-to-date research so you can make educated decisions about your investments.
Stock Market Advice
Date/Time (ET)SymbolRatingTermPrice (*)Target
12/19/2011 9:25 AM Buy
4.31 8.00
as of 12/30/2011
1 Week up  3.56 %
1 Month up  29.97 %
3 Months up  31.74 %
1 YTD up  34.80 %
Previous Recommendations
Date/Time (ET)SymbolRatingTermPrice (*)Target
11/16/2011 8:25 AM Buy
4.51 8.00
8/11/2011 9:25 AM Buy
4.47 6.00

(*) Stock Price at the time of the recommendation.
RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy